Aqara Adds Presence Sensor FP2 to its Smart Sensor Portfolio
20.4.2023 10:00:00 EEST | Business Wire | Press release
Aqara, a leading provider of smart home products, expands its wide-ranged smart sensor portfolio with the introduction of the Presence Sensor FP2, a revolutionary sensor for precise human presence detection. Equipped with the millimeter wave (mmWave) radar technology, the FP2 solves many pain points of the traditional passive infrared (PIR) presence sensors and enables a more tailored and rich smart home experience. The new sensor is now available on the Company’s Amazon brand stores in both North America (US, Canada) and Europe (France, Germany, Italy, Spain, UK) as well as selective Aqara retailers worldwide1.
Accurate human presence detection provides essential information for tailored smart home automations such as home security monitoring and energy management systems (e.g., automated lights, HVAC, home appliances control). The mmWave-based FP2 Presence Sensor takes a leap forward from the PIR motion sensors as the former detects a person’s presence with even the slightest movement such as the act of breathing. Gone are the frustrating experiences of having your smart lights turn off unintentionally because you were sitting still reading a book or working at the desk.
Moreover, the FP2 sensor raises the precision of human detection to the next level with its capability to monitor multiple zones and multiple targets simultaneously. The FP2 allows the user to define up to 30 zones within a room (up to 40 sq m/430 sq ft). For example, the living room and dining area can be configured as separate zones with individualized automations. This sensor tracks up to 5 persons at the same time2, making it possible to control different zones based on the real-time location of each family member. For instance, to dim the dining area lights and switch the TV on when the kids leave the dining table and move to the sofa, meanwhile to keep the kitchen light on when someone is washing the dishes.
The powerful capabilities of the FP2 sensor can also be used within the third-party smart home platforms including Apple Home, Amazon Alexa, Google Home, Home Assistant3 and more. Once the zones are set up in the Aqara Home app, the zone configuration can be synced to these platforms as multiple motion/occupancy sensors, allowing users to trigger zone-based automation with a wide variety of third-party smart home devices. Support of the new smart home standard, Matter, is also planned for the FP2, and will be added to the device via a subsequent OTA update4.
Aside from its precise presence detection and multi-zone automations, FP2 also has fall detection built-in5, which is particularly essential for senior citizens who are more vulnerable to fall injuries. Families and caregivers can be alerted by both local siren and remote alerts if the FP2 sensor detects a fall, which allows them to seek immediate assistance if necessary. The FP2 sensor can detect a fall at the home in a convenient way without the need to wear additional devices on the body. At the same time, unlike a typical security camera, the Sensor provides meaningful alerts and data without intruding on a person’s personal privacy.
Thanks to its powerful hardware, the FP2 sensor will be able to support much more cutting-edge features in the future such as posture detection, which not only recognizes falls but also other postures including standing, sitting, and lying. Sleep monitoring and respiratory rate detection capabilities could also be achieved via the FP2 in the future. These advanced features will be added to the FP2 sensor via future OTA updates4.
For more details of the Presence Sensor FP2, please visit our website.
- Product availability may vary among different retail channels, and could be updated all the time. It’s recommended to check with the regional retailer(s) for real-time availability.
- The best result can be achieved in the case of tracking not more than 3 persons.
- The FP2 sensor can be added to Home Assistant using HomeKit Controller integration.
- Some features of the FP2 sensor such as Matter support, posture detection and sleep monitor are not available by the time of launch.
- The Presence Sensor FP2 is not a medical device, and can only be used for notification purposes. Ceiling-mounted installation is required for fall detection, and the monitoring area will decrease when the FP2 is ceiling-mounted. In fall detection mode, many functionalities of the FP2 become unavailable, including zone positioning and multi-person detection.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230420005024/en/
Contact information
For Media Inquiry:
media@aqara.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Owkin to License K Pro AI Scientist and Multimodal Oncology and Immunology Data to Boehringer Ingelheim2.9.2026 15:00:00 EEST | Press release
Owkin, the agentic AI company striving to transform drug discovery and development for biopharma, today announced a license agreement with Boehringer Ingelheim for K Pro, Owkin’s AI Scientist, together with multimodal patient data, aiming to speed up the discovery process across multiple indications in oncology and immunology. This agreement builds upon an initial pilot undertaken by Owkin with Boehringer in 2025. In that pilot Owkin delivered deep spatial insights into the tumor microenvironment of a gene target through its MOSAIC dataset. Under the new agreement, Owkin will license multimodal oncology data to Boehringer and will generate new multimodal data in immunology. Owkin licenses, sources and generates multimodal patient data in collaboration with its global patient data network. Boehringer Ingelheim’s teams will access and analyze this data through K Pro, which provides a single environment to interrogate data and run reproducible analyses. K Pro’s reasoning capabilities supp
Biocytogen Enters into Non-Exclusive Licensing Agreement with Qilu Pharmaceutical for a Fully Human VHH Antibody to Support Innovative Drug Development in Neuroscience2.9.2026 15:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, SSE: 688796; HKEX: 02315) today announced that it has entered into a non-exclusive licensing agreement with Qilu Pharmaceutical Co., Ltd. (“Qilu Pharmaceutical”) for a fully human VHH antibody molecule. Under the agreement, Biocytogen will grant Qilu Pharmaceutical non-exclusive rights to a fully human VHH antibody molecule to support its research and development of innovative therapeutics in the neuroscience field. The licensed VHH antibody molecule was generated from Biocytogen’s proprietary RenNano® platform. The RenNano® platform is designed to discover fully human VHH antibody molecules with favorable specificity, binding affinity, and developability, and can generate molecular building blocks for the design and development of VHH antibodies, bispecific/multispecific antibodies, antibody-drug conjugates, and other innovative modalities. Through this license, Qilu Pharmaceutical may advance the research and development o
Croma-Pharma Introduces Electronic Instructions for Use Across the saypha ® Portfolio2.9.2026 14:37:00 EEST | Press release
Croma-Pharma has introduced electronic Instructions for Use (eIFU) across its saypha® portfolio in markets where applicable regulations permit electronic Instructions for Use to replace printed versions. The transition expands digital access to essential product information for healthcare professionals while reducing the use of printed documentation. Healthcare professionals can access the current approved Instructions for Use by scanning the QR code on the saypha® folding box. The eIFU platform provides direct digital access to the latest approved Instructions for Use. "Innovation extends beyond product development. It also includes how we provide healthcare professionals with access to essential product information," said Andreas Prinz, Chief Executive Officer of Croma-Pharma. "The introduction of electronic Instructions for Use across the saypha® portfolio reflects our focus on practical digital solutions that support healthcare professionals and align with evolving regulatory requi
Moving Forward in Oman: Orascom, Samih Sawiris and Muriya Keep Building2.9.2026 14:13:00 EEST | Press release
Across Oman, Orascom Development and its Sultanate platform, Muriya, are moving forward. While parts of the region grow cautious, Muriya has paused nothing, building and delivering across all three destinations: Hawana Salalah, Jebel Sifah and As Sodah Island. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260902781576/en/ Moving Forward in Oman: Orascom, Samih Sawiris and Muriya Keep Building (Photo: AETOSWire) The same steadiness runs through everything Samih Sawiris and Orascom have built, from El Gouna to Andermatt to Mamula Island: identifying extraordinary places and developing them for the long term. “Oman has everything we look for as a long-term developer: stability, natural beauty, and a clear direction for its future. Our continued investment across all three destinations reflects that conviction — we build for decades, and Oman is a country we intend to grow with in all circumstances.” — Naguib S. Sawiris, Chairm
Aukera Closes €460 Million Structured Credit Facility Led by EIG to Support European Energy Infrastructure Portfolio2.9.2026 14:00:00 EEST | Press release
Aukera, the pan-European battery storage and renewable energy platform backed by AtlasInvest, Reggeborgh and SFPIM (Belgium's sovereign wealth fund), announced the closing of its €460 million structured credit facility, for which EIG, a leading institutional investor in the global energy and infrastructure sectors, served as the lead investor. With the financing in place, Aukera moves into its next phase of growth, combining capital, expertise and delivery capability to build a significant European energy infrastructure platform that develops, finances, constructs and operates assets at scale. The original facility included an initial €200 million commitment and an accordion feature of up to €250 million. The amended facility converts that accordion into a firmly committed €260 million Series 2 tranche, increasing total committed capital to €460 million. The additional capital will support the continued advancement of Aukera's portfolio of renewable energy generation, battery storage a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
